Jan. 15, 2026 -- Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of fridge-free sterile injectable medicines, initially targeting anti-infective and oncology treatments in a total global market valued at over USD 6 billion. Stablepharma will apply its proprietary stabilisation technology, initially focused on vaccines, to non-vaccine sterile injectables that currently r

Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment U.S. enrollment evaluating SLS009 in combination with AZA/VEN in newly diagnosed AML with high-risk features is planned for Q1 2026, with European enrollment anticipated in Q2 2026 Jan. 14, 2026 -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of nov

Jan. 12, 2026 -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we believe will position long-read whole-genome sequencing as enabling infrastructure to support the development of individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases. Under the proposed collaboration, PacBio will provide its scientific expertise, and

$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategic holding of Orchestra BioMed since the Company’s formation Jan. 12, 2026 -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced

Jan. 06, 2026 -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 44th Annual J.P. Morgan Healthcare Conference, to take place January 12-15, 2026, in San Francisco, California. Mapi is actively seeking new partnerships for its new proprietary Depot products. Company management will be available for one-on-one meetings during the J.P. Morgan Healthca

Jan. 09, 2026 -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, to the Bio-Hermes studies. This collaboration will enhance the unique, observational platform studies that compare blood-based and digital biomarkers across a broad range of clinical cognitive conditions — along with MRI and PET images in Bio-Hermes-002 —as well as numerous races and ethnicities to gener

Jan. 07, 2026 -- Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing the investigational product, inhaled opelconazole, for patients suffering from serious acute and chronic respiratory diseases, today announced the decision to terminate its Opera-T Phase 3 Study with opelconazole in refractory Invasive Pulmonary Aspergillosis (IPA). This decision was based on an interim analysis for the purpose of a sample size recalculation when approximately 50% of the subjects

Jan. 07, 2026 -- BrightInsight, Inc. (“BrightInsight”), a leader in digital health solutions, today shared new data from its collaboration with Sanofi and its partner, Regeneron, highlighting the positive impact of the Patient App on adherence and persistence for one of Sanofi and Regeneron’s key biologic therapies. Adherence remains a major challenge for the pharmaceutical industry—particularly with self-injected therapies administered at home. Despite substantial investment in traditional pa

Jan. 07, 2026 -- Relation and healthcare investment firm Deerfield Management, a current investor, today announced the establishment of a new research collaboration to advance therapeutic discovery projects for diseases of high unmet need. “The opportunity to combine Relation’s and Deerfield’s capabilities across AI, biology, discovery and development is a compelling proposition,” said David Roblin, MD, CEO of Relation. “We believe that this partnership will enable us to expand our R&D efforts

- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically significant activity on all four key secondary efficacy endpoints - - Obexelimab was well tolerated and no new safety signals were observed - - Zenas anticipates submitting a Biologics License Application (BLA) to the FDA in the second quarter of 2026 and a Marketing Authorization Application